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Background: The aim of  this study was to determine the prevalence and factors associated with microalbuminuria among 
newly diagnosed diabetic patients in Mulago National Referral Hospital, Uganda.
Methods: In this cross-sectional study conducted between June 2014 and January 2015, we collected information on patients' 
socio-demographics, biophysical profile, blood pressure, biochemical testing and echocardiographic findings using a pre-tested 
questionnaire. Bivariate and multivariate logistic regression analyses were used to investigate the association of  several factors 
with microalbuminuria.
Results: Of  the 175 patients recruited, males were 90(51.4%) and the mean age was 46±15 years. Majority of  patients had type 
2 DM 140 (80.0%) and the rest had type 1 DM 35 (20.0%). Mean glycated hemoglobin (HbA1C) was 13.9±5.3%. Mean duration 
of  diabetes was 2 months. Prevalence of  microalbuminuria was 47.4 % (95% CI: 40.0%-54.9%) overall. Pregnancy was associat-
ed with microalbuminuria (OR7.74[95%CI.1.01-76.47] P=0.050) while mild and moderate physical activity at work were inverse-
ly associated with microalbuminuria respectively (OR0.08[95%CI0.01-0.95] P=0.046) and (OR0.07[95%CI0.01-0.77] P=0.030).
Conclusion: Prevalence of  microalbuminuria was high in this group. Physical activity at work may be protective against micro-
albuminuria and this calls for longitudinal studies. Early detection and management of  microalbuminuria in diabetics may slow 
progression to overt diabetic nephropathy (DN).
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Microalbuminuria is an early marker of  nephropathy, car-
diovascular diseases and severe ocular morbidity in adults 
with diabetes1-5. It is a sub-clinical condition that is asso-
ciated with high morbidity and mortality5,6. DM is one of  
the leading causes of  microalbuminuria in SSA5,7,8.
The presence of  microalbuminuria precedes the develop-
ment of  overt diabetic nephropathy by 10–14 years. It is 
at this stage that one can reverse diabetic nephropathy or 
prevent its progression5,8-10. Unfortunately, tests to detect 
microalbuminuria in diabetics are not routinely done in 
Uganda and sub-Saharan Africa (SSA) as a whole.
Among persons with DM, microalbuminuria has been 
estimated to be twice the prevalence in the general popu-
lation in Africa5,11,12. Approximately half  the patients with 
microalbuminuria will progress to overt proteinuria over 
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the next decade6,13. Therefore, early detection and appro-
priate interventions in asymptomatic individuals may help 
in preventing deterioration in renal function, progression 
to diabetic nephropathy and ESRD5.
Therapeutic interventions which reverse microalbumin-
uria include intensified glycemic control, use of  Angio-
tensin Converting Enzyme (ACE) inhibitors and these 
should be initiated in diabetics with microalbuminuria to 
prevent progress to overt diabetic nephropathy12.
DN, the end result of  microalbuminuria, is a major cause 
of  morbidity, premature mortality, end stage renal dis-
ease,  need for renal replacement therapy, cardiovascular 
diseases, and escalating health-care costs in diabetic pa-
tients6,12,14-18. The prevalence of  DN is increasing steeply 
along with the diabetes epidemic15. Approximately one 
third to half  of  patients with diabetes develops renal 
manifestations14,15,19.
DN may be more frequent among patients  in Africa as 
compared to those in the developed world due to delayed 
diagnosis, limited screening and diagnostic resources, 
poor glycemic control and inadequate treatment of  mi-
croalbuminuria14,19,20.
From studies in the western world, the factors associated 
with microalbuminuria have been elucidated.5,6,12. In Afri-
ca, there is paucity of  data on the prevalence and factors 
associated with of  microalbuminuria among diabetic pa-
tients5,14.
Therefore this study sought to determine the prevalence 
and factors associated with microalbuminuria among 
newly diagnosed diabetic patients at Mulago National Re-
ferral Hospital in Uganda.
 
Methods
Study design and participants
This was a cross-sectional study among 175 newly diag-
nosed diabetic patients at Mulago National referral hospi-
tal in Uganda conducted between June 2014 and January 
2015. DM was diagnosed using the standard criteria of  
fasting blood sugar of  ≥6.9 mmol/L. All newly diag-
nosed diabetic patients aged 18 years and above attend-
ing the diabetic clinic or admitted to the medical wards 
of  Mulago hospital during the study period who met the 
inclusion criteria and provided informed consent were re-
cruited consecutively. We excluded patients with urinary 
tract infection and patients who were unable to provide 
information.
Operational definitions
Microalbuminuria was defined as Albumin to Creatinine 
Ratio (ACR) between 30 and 299 mg/g
Type1 DM: This referred to patients who required in-
sulin and were depending on insulin for glucose control 
since diagnosis.
Type 2 DM: Patients were classified as having type 2 di-
abetes mellitus if  they required oral hypoglycemic agents 
or usage of  combination of  insulin and the oral hypogly-
cemic agents for glucose control.
Classification of  physical activity
At work (8 hours of  the day for 5 days per week):
1. Sedentary: mainly sedentary (sitting e.g. reading, work-
ing with computer)
2. Mild: predominantly walking on one level, standing, no 
heavy lifting
3. Moderate: mainly climbing stairs, peasantry activity
4. Strenuous: heavy physical labour e.g. lifting heavy ob-
jects
During leisure (3 hours per day for at least 4 days of  
the week):
1. Sedentary: sitting e.g. reading, discussions, watching 
television, social media, video games
2. Mild: minimal effort e.g. walking <1kmm, light sport, 
light gardening
3. Moderate: (e.g. walking >1km, bicycle riding, golf  at 
least 4hours per week)
4. Strenuous : ( heart beats rapidly e.g. running/jogging, 
football, basketball, rugby, vigorous swimming)
Study setting
The study was carried out in the diabetic out-patient clin-
ic, the medical endocrine ward and the medical emergen-
cy ward of  Mulago National referral Hospital. Mulago 
is a National Referral Hospital in Uganda and Teaching 
Hospital for Makerere University with a bed capacity of  
1500. Mulago Hospital receives referrals from all parts of  
the country including referrals from neighboring coun-
tries like Southern Sudan, the Democratic Republic of  
Congo, Rwanda among others. The study population is 
representative of  the Ugandan diabetic population.
Sample size estimation
Using prevalence of  17% for microalbuminuria among 
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diabetic patients as determined by Son MK et al1, a sam-
ple size of  180 was estimated using the Kish Leslie (1965) 
formula.
N= Z2P(1-P)
           D2
N =   Sample size 180
Z =   1.96, the normal value corresponding to the 95% 
confidence interval
P =    0.17, prevalence from the above study,   D =    0.05, 
Acceptance error.
However data from 5 participants was not included be-
cause it was incomplete. Therefore we analyzed data from 
175 participants.
Clinical assessment
We took a focused history and performed a specific phys-
ical exam to determine the biophysical measurements. 
Information gathered was entered into a pre-tested ques-
tionnaire. We assessed the following factors: patients’ 
demographic data, history of  hypertension, age, physical 
exercise, marital status, date of  diagnosis of  DM, drug 
history, occupation, education level, and Last Normal 
Menstrual Period (LNMP).
Weight was measured using a Secco weighing scale to 
the nearest Kg, height was measured in meters using a 
non-stretchable tape and these were used to compute 
Body Mass Index (BMI). Waist and hip circumferences 
were measured and waist to hip ratios determined for all 
patients.
Glycated haemoglobin (HbA1C) was measured by auto-
mated high performance liquid chromatography. Other 
investigations included urinalysis and Microalbuminuria 
using ACR.
Echocardiography parameters were acquired using a 
commercially available machine, Phillips HD11XE (Eind-
hoven, The Netherlands) with 2-D, MMode and Doppler 
capabilities was used according to the American Society 
of  Echocardiography21.
All equipment used were calibrated to avoid measure-
ment bias.
Assessment of  microalbuminuria
We explained to participants the procedure for collecting 
a mid-stream urine sample. Each participant was given 
two urine containers and instructed to provide 2 separate 
samples of  mid-stream urine each measuring 10 ml. One 
of  the containers was sterile and the sterile sample was 
used for urinalysis including urine microscopy. We ex-
cluded participants who were found to have urinary tract 
infection and we started them on antibiotics. The second 
container collected a spot urine sample for measurement 
of  urine albumin to creatinine ratio (ACR). Microalbu-
minuria was defined as ACR between 30 and 299 mg/g.
Blood pressure measurement
Blood pressure was measured using a mercury sphygmo-
manometer and an average of  the 2 readings was used in 
the analysis.
We instructed each participant to sit on a chair with both 
feet resting on the floor uncrossed and rest for 5 min-
utes before taking the 2 blood pressure readings. The two 
blood pressure readings were recorded 5 minutes apart 
using a standard manual dekametaccoson MK3 mercury 
sphygmomanometer.
The patient exposed the arm from which blood pressure 
was to be measured and rested it on a table at the level of  
the heart. A blood pressure cuff  (with a bladder length 
> 80% of  the arm circumference) was placed 2cm above 
the antecubital fossa. We inflated the cuff  while feeling 
for the patient’s radial pulse.
The estimate of  the systolic blood pressure was obtained 
by inflating the cuff  30 mmHg above the point of  dis-
appearance of  the radial pulse. We then placed the dia-
phragm of  the stethoscope on the antecubital fossa and 
the cuff  deflated at 2 mmHg per second while listening 
for korotkoff  sounds.
Korotkoff  sounds 1 and 2 represented systolic and dia-
stolic blood pressures respectively. For cases where Korot-
koff  sounds remained audible despite complete deflation 
of  the cuff, abrupt muffling of  the sounds was used to 
denote diastolic blood pressure. We recorded the aver-
age of  the 2 blood pressure readings. Participants were 
declared hypertensive if  they; were on anti-hypertensive 
medication, had history of  hypertension and/or evidence 
of  hypertension (blood pressure ≥140/90 mmHg).
Ethical approval
Institutional consent was sought from the department of  
Medicine Makerere University, Mulago National Referral 
Hospital and School of  Medicine Research and Ethics 
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Committee (SOMREC) of  Makerere University College 
of  Health Sciences. All study participants provided writ-
ten informed consent for involvement in the study. En-
rolment was totally free and voluntary and participants 
were free to withdraw at any time without any conse-
quences to them. The patients’ records/information was 
anonymized and de-identified prior to analysis.
Data management and analysis
Data was double entered in a database developed with EP-
IDATA version 3.1, validated and inconsistences cleared 
then  exported to STATA 13 for analysis. Continuous 
data was summarized using measures of  central tenden-
cy while categorical data was summarized as frequencies 
and percentages and presented in tables. Prevalence was 
presented as percentages with their confidence intervals. 
Comparisons were made using the student t-test for the 
continuous data and xhi-square or fisher’s exact test for 
the categorical data.
The outcome was dichotomized as having microalbumin-
uria or not then logistic regression was used to determine 
the association between the predictors and microalbu-
minuria. This was presented as Odds ratio (OR) and their 
95% confidence interval (CI). Only factors with P- value 
<0.2 at bivariate analysis were considered for multivariate 
analysis. Multivariate logistic regression was performed; 
interaction was assessed for using the Chunk test. Con-
founding was assessed for using a 10% difference be-
tween the crude and adjusted models. Significance was at 
p value of  0.05 and less.
Results
Characteristics of  newly diagnosed diabetic patients 
at Mulago National referral hospital who participat-
ed in the study.
This study recruited 175 newly diagnosed diabetic pa-
tients between June 2014 and January 2015. Of  these, 
90(51.4%) were males. The mean age of  all the partici-
pants was 46±15 years. Majority of  patients had type 2 
DM, 140 (80.0%) and the rest had type 1 DM, 35 (20.0%). 
The mean HbA1C was 13.9±5.3%. Mean duration of  di-
abetes was 2 months. (Table 1 and table 2).
Table 1. Social demographic characteristics of newly diagnosed diabetic patients at Mulago 
National referral hospital who participated in the study.(N=175). 
 




Age <40 years 50 (28.5) 25(50.0) 25(50.0) 
40 years and above 125 (71.5) 58(46.4) 67(53.6) 
Gender Male 90 (51.4) 46(31.1) 44(48.9) 
Female 85 (48.6) 37(43.5) 48(56.5) 
Employment Employed 66 (37.7) 31(47.0) 35(53.0) 
Unemployed 108 (62.3) 51(47.2) 57(52.8) 
Pregnancy Yes 6 (6.3) 5(83.3) 1(16.7) 
No 90 (93.7) 38(42.2) 52(57.8) 
Education None 14 (8.5) 7(50.0) 7(50.0) 
Primary 71 (6.6) 33(46.5) 38(53.5) 
Secondary 64 (36.6) 29(45.3) 35(54.7) 
Tertiary 26 (14.9) 14(53.9) 12(46.2) 
Marital status Never married 26 (14.9) 14(53.9) 12(46.1) 
Currently married 104 (59.4) 48(46.1) 56(53.9) 
No longer married 45 (25.7) 21(46.7) 24(53.3) 
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Prevalence of  microalbuminuria
Prevalence of  microalbuminuria was 47.4 % (95% CI: 
40.0%-54.9%) among all the patients that were assessed 
in the study. Among these patients, females had a higher 
prevalence of  microalbuminuria, of  43.5% compared to 
males with 31.1%. Type 1 DM patients had a higher prev-
alence of  microalbuminuria 19(54.3%) compared to 64( 
45.7%) among type 2 DM. Patients with central obesity 
as measured by waist hip ratio had a higher prevalence of  
Microalbuminuria of  57.7% compared to those without 
central obesity whose prevalence was 49.6%. Table 2.
Factors associated with microalbuminuria.
In bivariate analysis, the factors associated with microal-
buminuria included: being overweight and obesity. (Refer 
to Table 3).




Physical activity at 
work
Sedentary 17 (9.8) 11(64.7) 6(35.3)
Mild 48 (27.7) 23(47.9) 25(52.1)
Moderate 71 (41.0) 33(46.5) 38(53.5)
Strenuous 37 (21.4) 15(40.5) 22(59.5)
Physical activity at 
leisure
Sedentary 123 (70.3) 60(48.8) 63(51.2)
Moderate 52 (29.7) 23(44.2) 29(55.8)
DM type Type 1 35 (20.0) 19(54.3) 16(45.7)
Type 2 140 (80.0) 64(45.7) 76(54.3)
Hypertension Hypertensive 108 (61.7) 47(43.5) 61(56.5)
Normotensive 67 (38.3) 36(53.7) 31(46.3)
BMI (kg/m2) Underweight (<19∙0) 33 (18.9) 23(69.7) 10(30.3)
Normal weight (19∙0-
<25∙0)
70 (40.0) 35(50.0) 35(50.0)
Over weight 
(25∙0-<30∙0)
42 (24.0) 13(31.0) 29(69.0)
Obesity (≥30∙0) 30 (17.1) 12(40.0) 18(60.0)
Waist hip 
ratio
Normal 123 (70.3) 61(49.6) 62(50.4)
Abnormal 52 (29.7) 30(57.7) 22(42.3)
HbA1C% <7% 14 (8.1) 3(21.4) 11(78.6)
>7% 158 (91.9) 79(50.0) 79(50.0)
Drugs ACEI/ARBs 9 (5.1) 4(44.4) 5(55.6)
CCB 12 (6.9) 3(25.0) 9(75.0)
Beta blockers 4 (2.3) 2(50.0) 2(50.0)
Ejection fraction % >50% 139 (79.5) 65(46.8) 74(53.2)
<50% 36 (20.5) 18(50.0) 18(50.0)
LVH Present 98 (56.0) 42(42.9) 56(57.1)
Absent 77 (44.0) 41(53.3) 36(46.7)
Diastolic function Normal 83 (47.4) 43(51.8) 40(48.2)
Impaired 92 (52.6) 40(43.5) 52(56.5)
Wall motion Normal 170 (97.1) 81(47.6) 89(52.4)
Abnormal 5 (2.9) 2(40.0) 3(60.0)
Table 2: Characteristics of newly diagnosed diabetic patients at Mulago National referral 1 
hospital who participated in the study.(N=175). 2 
 ACEI   Angiotensin Converting Enzyme Inhibitors,   CCB Calcium Channel  Blocker
 ARB   Angiotensin receptor Blocker.     N         Numbers,     %  Percentage.
 BMI Body Mass Index      DM  Diabetes Mellitus,  LVH   Left Ventricular Hypertrophy
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After adjusting for patients’ sex, age, hypertension, an-
ti-hypertensive drugs and  level of  HbA1C, the only 
significant factor associated with microalbuminuria was 
pregnancy (OR7.74[95%CI.1.01-76.47] P=0.050) while 
mild and moderate physical activity at work were in-
versely associated with microalbuminuria respectively 
(OR0.08[95%CI0.01-0.95] P=0.046) and (OR0.07[95%-
CI0.01-0.77] P=0.030). Overweight and obesity has no 
significant association with microalbuminuria. (Refer to 
Table 3).
Discussion
In this study, we found a high prevalence of  microal-
buminuria among diabetic patients who were newly di-
agnosed with the disease. Approximately half  of  all 
participants had significant microalbuminuria (47.4%). 
Prevalence of  microalbuminuria among type 1 diabetics 
was 54.3 while type 2 diabetic patients had 45.7%. The 
prevalence is rather higher than what Mi Kyung et al 
found in a prospective study of  patients with type 1 DM. 
In their population, type 1 diabetic patients had preva-
lence of  Microalbuminuria of  17%. Mi Kyung et al as-
sessed adolescents with median age of  18.9 years while 
our population had a mean age of  46±15 years, the effect 
of  age could explain the difference. Alleyn in a prospec-
tive cohort study noted that approximately one third of  
persons with Type 1 DM develop microalbuminuria6,22,23. 
The prevalence we found was slightly higher than Alleyn’s 
estimate possibly because of  advanced age for our patient 
population compared to their population of  adolescents.
Among type 2 diabetic patients, we found a prevalence of  
45.7% which is comparable to findings by Mi Kyung et 





Sex Male 44(48.9) 46(51.1) 1.00 1.00
Female 48(56.5) 37(43.5) 0.74(0.41-1.34) 0.316 1.21 (0.26-5.70) 0.802
Age <40 years 25(50.0) 25(50.20 1.00 1.00
40 and above 67(53.6) 58(46.4) 0.87(0.45-1.67) 0.667 1.11 (0.24-5.16) 0.891
Pregnancy No 52(57.8) 38(42.2) 1.00 1.00





Sedentary 6(35.3) 11(64.7) 1.00 1.00
Mild 25(52.1) 23(47.9) 0.47(0.16-1.42) 0.183 0.08 (0.01-0.95) 0.046
Moderate 38(53.5) 33(46.5) 0.37(0.11-1.22) 0.104 0.07 (0.01-0.77) 0.030
Strenuous 22(59.5) 15(40.5) 0.55(0.03-1.37) 0.687 0.19 (0.13-2.73) 0.223
Physical activity 
at leisure
Sedentary 63(51.2) 60(48.8) 1.00
Moderate 29(55.8) 23(44.2) 0.83(0.43-1.59) 0.582
HbA1C Normal 11(78.6) 3(21.4) 1.00 1.00
Abnormal 79(50.0) 79(50.0) 3.67(0.99-13.65) 0.053 2.28 (0.32-16.16) 0.408
Hypertension Normotensive 31(46.3) 36(53.7) 1.00 1.00
Hypertensive 61(56.5) 47(43.5) 0.66(0.36-1.22) 0.189 2.38 (0.66-8.57) 0.183
Drugs ACEI/ARBs 5(55.6) 4(44.4) 0.88(0.23-3.40) 0.854
CCBs 9(75.0) 3(25.0) 0.35(0.90-1.32) 0.121 0.38 (0.06-2.27) 0.289
Beta blockers 2(50.0) 2(50.0) 1.11(0.15-8.07) 0.917
DM type Type 1 16(45.7) 19(54.3) 1.00 1.00
Type 2 76(54.3) 64(45.7) 0.71(0.34-1.49) 0.365 0.52 (0.08-3.56) 0.507
BMI Normal weight 45(43.7) 58(56.3) 1.00 1.00
Over wt & 
Obesity
47(65.3) 25(34.7) 0.41(0.22-0.77) 0.005 0.37 (0.12-1.13) 0.082
Ejection fraction >50% 74(53.2) 65(46.8) 1.00
<50% 18(50.0) 18(50.0) 1.14(0.55-2.37) 0.729
LVH Absent 36(46.7) 41(53.3) 1.00
Present 56(57.1) 42(42.9) 0.66(0.36-1.20) 0.173
Table 3: Logistic regression for factors associated with microalbuminuria among newly diagnosed 1 
diabetic patients at Mulago hospital. 2 
OR   Odds Ratio              N   Number                %   Percentage
CI    Confidence IntervalBMI Body Mass Index      DM  Diabetes Mellitus,  LVH   Left Ventricular Hypertrophy
ACEI  Angiotensin converting enzyme inhibitor,  ARB   Angiotensin receptor Blocker,  CCB  Calcium Channel Blocker.
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al, they had  a prevalence of  microalbuminuria of  44.4% 
among type 2 diabetic patients1. This high prevalence may 
be due to a period of  latency for patients with type 2 DM 
before diagnosis. Chowta et al in a cross-sectional study 
reports that in type-2 diabetics, microalbuminuria ranges 
from 8–47%12,24,25. These findings are in agreement with 
our findings for patients with type 2 DM. Three other 
cross-sectional studies among type 2 diabetic patients in 
Nepal and Bangladesh consistently reported a high prev-
alence of  microalbuminuria ranging from 30-47%26-28. 
The high prevalence of  microalbuminuria among type 2 
diabetic patients cannot be over emphasized in Uganda, 
a country with majority of  diabetic patients having type 2 
DM.  Jean Jacques added more evidence to the fact that 
approximately one third to half  of  patients with DM de-
velops renal complications14,29.
In our patient population, age had no effect on the degree 
of  MA and   Lampropoulou reached a similar conclusion 
in their study where age showed just a weak correlation 
with MA16,30. Although microalbuminuria was more com-
mon in participants 40 years and older in our study, this 
is predictable because age and diabetes duration for more 
than 10 years are well known risk factors for the develop-
ment of  diabetic nephropathy16.
We found the prevalence of  microalbuminuria to be 
more common among females and Okpere et al came to a 
similar conclusion in their study of  Nigerian adolescents. 
Similarly patients who had central obesity in our study 
had  a higher prevalence of  MA compared to those with-
out central obesity, Okpere reports similar findings5.
The prevalence of  microalbuminuria we found of  47.4% 
is 3 times higher than that of  the general population 
which is reported to be 10 – 15%5. However most of  this 
evidence is from the developed world and  in Africa, there 
is paucity of  data on the prevalence of  microalbuminuria 
both in the general population and among diabetics5.
Among diabetic patients, microalbuminuria predicts the 
development of  overt diabetic nephropathy5. Therefore a 
high prevalence we found predicts a great burden of  re-
nal disease for our patient population if  no interventions 
are done.
In our study, microalbuminuria had no significant asso-
ciation with BMI and this is in keeping with finding by 
Chowta et al who found that there is no effect of  BMI 
and sex on the prevalence of  microalbuminuria12. Like-
wise sex had no significant association with microalbu-
minuria in this study. Patients who exercised mildly and 
moderately during work were less likely to develop mi-
croalbuminuria. This makes exercise a possible protective 
factor against microalbuminuria among diabetics.
Pregnant patients in our study were seven times more 
likely to have significant microalbuminuria compared 
with those who were not pregnant. The possible reason 
could be the pregnancy associated protein loss and like-
ly hypertension in pregnancy. These are potential con-
founders in our study.
Physical activity at work was inversely associated with mi-
croalbuminuria in this study. In SSA, this is one of  the 
first studies to describe a relationship between microal-
buminuria and physical activity at work. To better under-
stand the long term effect of  physical activity at work on 
kidney function among diabetic patients in Africa, there 
is need for longitudinal studies.
We found no association of  microalbuminuria with gly-
cemic control as measured by HbA1C. This is different 
from findings by Alleyn. In their study, microalbuminuria 
occurred in association with poor glycemic control and 
elevated blood pressure6. In addition hypertension had 
no significant association with microalbuminuria in this 
study which is in contrast with findings by Alleyn. The 
differences could be due to the differences in age for the 
two populations. Alleyn assessed a predominantly young 
population of  type 1 diabetics while we assessed a popu-
lation with mean age of  46±15 years. In addition Alleyn 
followed up their cohort for 2 years yet ours was  a cross 
sectional study6.
Gender was not associated with microalbuminuria in this 
study although the prevalence of  microalbuminuria was 
higher among females than males; this difference was not 
statistically significant. Chowta et al reported similar find-
ings: There was no correlation between  gender and mi-
croalbuminuria in type-2 diabetes mellitus12,31.
Studies in the western world show a positive correlation 
between degree of  microalbuminuria, BMI and blood 
pressure12; these findings are different from evidence 
generated in our study where  there is no association of  
microalbuminuria with hypertension and BMI. Asadujja-
man et al reached a similar conclusion is a cross-sectional 
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study in Bangladesh which found no association between 
microalbuminuria and BMI among diabetic patients28. 
However, Khadka et al in a cross sectional study among 
type 2 diabetic patients in Nepal found hypertension to 
be associated with microalbuminuria26.
Evidence shows that DN is more frequent among pa-
tients in Africa as compared to those in the developed 
world. Possible reasons include delay in diagnosis, limited 
screening/diagnostic resources, poor control of  blood 
sugar and blood pressure  and inadequate treatment at 
an early stage14,19,20. However, evidence on the burden of  
kidney diseases in people with diabetes in Africa remains 
very patchy14. A meta-analysis in sub-Saharan Africa has 
found the prevalence of  DN to be 36%32, while in China 
DN is only present in 8%  of  diabetic patients33.
We recognize that the lack of  a non-diabetic control pop-
ulation is a limitation of  our study; however, this study 
was not designed to determine the effect of  diabetes on 
the kidney, but rather to explore the magnitude of  sub-
clinical microalbuminuria among newly diagnosed dia-
betic patients in the SSA context, including the factors 
associated with microalbuminuria.
The short duration of  the study could have obscured sea-
sonal variability. This was due to limitations in logistics: 
however newly diagnosed diabetic patients were recruited 
consecutively over a seven months period.
We did not analyze data from 5 participants because it 
was incomplete. This limitation could have affected the 
power of  the study.
Conclusion
Prevalence of  microalbuminuria was high in this patient 
population of  newly diagnosed diabetes mellitus. Preg-
nancy was positively associated with significant microal-
buminuria while physical activity at work was inversely 
associated with microalbuminuria. Early detection and 
management of  microalbuminuria may help in prevent-
ing deterioration in renal function and development of  
overt diabetic nephropathy and progression to ESRD. 
Physical activity at work may have a protective effect 
against microalbuminuria and DN; longitudinal studies 
on this subject are needed.
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